{"id":59488,"date":"2023-01-25T12:41:51","date_gmt":"2023-01-25T02:11:51","guid":{"rendered":"https:\/\/www.aumanufacturing.com.au\/?p=59488"},"modified":"2023-01-25T15:03:04","modified_gmt":"2023-01-25T04:33:04","slug":"clinical-trial-on-schedule-and-600000-in-rd-funding-accessed-emvision","status":"publish","type":"post","link":"https:\/\/www.aumanufacturing.com.au\/clinical-trial-on-schedule-and-600000-in-rd-funding-accessed-emvision","title":{"rendered":"Clinical trial on schedule and $600,000 in R&D funding accessed: EMVision"},"content":{"rendered":"
Brain imaging technology company EMVision <\/span>Medical Devices has given an update on progress of its clinical trial and a Medical Research Future Fund-backed R&D program, with the latter seeing the company access a $600,000 milestone payment.<\/span><\/p>\n The clinical trials <\/span><\/a>are in the pre-validation phase and running to schedule, according to a statement from EMVision on Wednesday.\u00a0<\/span><\/p>\n EMVision is currently developing a first-generation scanner for bedside use in emergency departments and other clinical settings, in parallel with a <\/span>second-generation version designed for first responders<\/span><\/a>. These are an alternative to CT and MRI scans and designed for detection of strokes at a critical early stage.<\/a><\/span><\/p> Approximately half of 30 participants for Stage 1 (healthy volunteers) have successfully enrolled in the clinical trial, with all 30 expected to be enrolled \u201cin the coming weeks\u201d, said EMVision. This will activate Stage 2 of the trial, \u201cinvolving up to 150 acute stroke\/stroke mimic patients.\u201d\u00a0<\/span><\/p>\n The trial involves the first-generation bedside machine (pictured.)<\/span><\/p>\n \u201cWe have strong clinical engagement and the ease of training and use of our device<\/a>, along with the speed of scanning, has certainly helped with the process,” said <\/span>CEO Dr Ron Weinberger.<\/span>\u00a0<\/span><\/p> Weinberger\u2019s company also gave an update on <\/span>its five-year project, which was awarded $8 million in funding from the Australian government\u2019s Medical Research Future Fund (MRFF) program<\/a>, and is being carried out in partnership with the Australian Stroke Alliance (ASA.) This covers a more portable, second-generation scanner, with the company targeting trials in road and air ambulances next year.<\/span><\/p>\n Funding is released in a stage-gated approach throughout the project, with the latest a $600,000 payment.<\/span><\/p>\n \u201cThe testing conducted as part of our ASA milestones has shown encouraging benchtop results from our system enhancements which bodes well for our clinical trials,\u201d added Weinberger.\u00a0<\/span><\/p>\n \u201cWe are excited with the progress being made with our 2<\/span>nd<\/span> Gen first responder model as well as our 1st Gen in-hospital device<\/a>.\u201d<\/span><\/p>\n